AFP and metabolic dysfunction-associated steatotic liver disease: The variables loss of appetite, abdominal pain or discomfort, NAFLD, ascites, family history of malignancies, antiviral treatment, traditional medication, duration of T2D, CPS, maximum tumour size, HCC treatment, total bilirubin (TBil), alkaline phosphatase (ALP) level, and AFP level were significantly different (p < 0.05) between alive and dead patients.